Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective.
Saved in:
| Title: | Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective. |
|---|---|
| Alternate Title: | Comparação dos custos de dupilumabe e omalizumabe para o tratamento de pacientes com asma alérgica grave na perspectiva do sistema de saúde privado brasileiro. |
| Authors: | Bighetti Magro, Frederico José1 frederico.magro@sanofi.com, Barbosa, Aline1, Taminato, Alexandre1, Borges Migliavaca, Celina2, Federico, Priscila1, Nahuys Tebyriçá, Renata1, Cançado, Jose Eduardo D.3, Giavina-Bianchi, Pedro4, Falavigna, Maicon2 |
| Source: | JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde. Dec2022, Vol. 14 Issue 3, p247-252. 6p. |
| Subjects: | DUPILUMAB, ASTHMATICS, OMALIZUMAB, IMMUNOGLOBULIN E, MEDICAL care, ELECTROCONVULSIVE therapy |
| Abstract (English): | Objective: To compare the costs of dupilumab and omalizumab for treating severe allergic asthma patients from the perspective of the Brazilian private healthcare system. Methods: Using clinical and demographic inputs from the literature, we simulated a cohort of 5,000 severe allergic asthma patients and estimated the treatment cost with omalizumab. Results: In the simulated cohort, 81.3% were female, the mean body weight was 75.1 kg (SD 13.1), and the mean serum IgE was 532 IU/mL (SD 688). All patients were eligible for treatment with dupilumab, but 830 (16.6%) were ineligible for treatment with omalizumab due to serum IgE level and/or body weight combinations, according to the product label. Over four weeks, the mean dose of omalizumab was 537 mg (SD 285). The annual mean per-patient cost for treatment with omalizumab was BRL 110,783.89 (SD 58,385.81), ranging from BRL 31,797.49 to BRL 246,643.15. The treatment cost with dupilumab is BRL 111,724.21 for the first year and BRL 107,599.91 for subsequent years. Conclusions: We observed slightly lower mean treatment costs with dupilumab than with omalizumab. However, while the treatment cost with dupilumab is fixed and predictable, the treatment cost with omalizumab is highly variable, depending on patients’ characteristics. Health managers should consider these findings for reimbursement and clinical protocol development decisions. [ABSTRACT FROM AUTHOR] |
| Abstract (Portuguese): | Objetivo: Comparar os custos de dupilumabe e omalizumabe para o tratamento de pacientes com asma alérgica grave na perspectiva do sistema de saúde privado brasileiro. Métodos: Utilizando parâmetros clínicos e demográficos a partir de dados da literatura, simulamos uma coorte com 5.000 pacientes com asma alérgica grave e estimamos o custo de tratamento com o omalizumabe. Resultados: Na coorte simulada, 81,3% eram do sexo feminino, com peso médio de 75,1 kg (DP 13,1) e IgE sérica de 532 IU/mL (DP 688). Todos os pacientes eram elegíveis para o tratamento com dupilumabe, porém 830 (16,6%) não eram elegíveis para o tratamento com omalizumabe devido a combinações específicas de IgE sérica e/ou peso corporal, de acordo com a bula do produto. Para o período de 4 semanas, a dose média de omalizumabe foi de 537 mg (DP 285). O custo médio anual por paciente do tratamento com omalizumabe foi de R$ 110.783,89 (DP 58.385,81), variando de R$ 31.797,49 a R$ 246.643,15. O custo do tratamento com dupilumabe é de R$ 111.724,21 no primeiro ano e R$ 107.599,91 nos anos seguintes. Conclusões: Foi observado que o custo médio do tratamento com dupilumabe é ligeiramente menor que o custo com omalizumabe. Todavia, enquanto o custo do tratamento com dupilumabe é fixo e previsível, o custo do tratamento com omalizumabe é altamente variável, dependendo de características dos pacientes. Esses achados devem ser considerados pelos gestores de saúde para decisões sobre reembolso e desenvolvimento de protocolos clínicos. [ABSTRACT FROM AUTHOR] |
| Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 161425621 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Comparação dos custos de dupilumabe e omalizumabe para o tratamento de pacientes com asma alérgica grave na perspectiva do sistema de saúde privado brasileiro. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Bighetti+Magro%2C+Frederico+José%22">Bighetti Magro, Frederico José</searchLink><relatesTo>1</relatesTo><i> frederico.magro@sanofi.com</i><br /><searchLink fieldCode="AR" term="%22Barbosa%2C+Aline%22">Barbosa, Aline</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Taminato%2C+Alexandre%22">Taminato, Alexandre</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Borges+Migliavaca%2C+Celina%22">Borges Migliavaca, Celina</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Federico%2C+Priscila%22">Federico, Priscila</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Nahuys+Tebyriçá%2C+Renata%22">Nahuys Tebyriçá, Renata</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Cançado%2C+Jose+Eduardo+D%2E%22">Cançado, Jose Eduardo D.</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Giavina-Bianchi%2C+Pedro%22">Giavina-Bianchi, Pedro</searchLink><relatesTo>4</relatesTo><br /><searchLink fieldCode="AR" term="%22Falavigna%2C+Maicon%22">Falavigna, Maicon</searchLink><relatesTo>2</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22JBES%3A+Brazilian+Journal+of+Health+Economics+%2F+Jornal+Brasileiro+de+Economia+da+Saúde%22">JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde</searchLink>. Dec2022, Vol. 14 Issue 3, p247-252. 6p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22DUPILUMAB%22">DUPILUMAB</searchLink><br /><searchLink fieldCode="DE" term="%22ASTHMATICS%22">ASTHMATICS</searchLink><br /><searchLink fieldCode="DE" term="%22OMALIZUMAB%22">OMALIZUMAB</searchLink><br /><searchLink fieldCode="DE" term="%22IMMUNOGLOBULIN+E%22">IMMUNOGLOBULIN E</searchLink><br /><searchLink fieldCode="DE" term="%22MEDICAL+care%22">MEDICAL care</searchLink><br /><searchLink fieldCode="DE" term="%22ELECTROCONVULSIVE+therapy%22">ELECTROCONVULSIVE therapy</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Objective: To compare the costs of dupilumab and omalizumab for treating severe allergic asthma patients from the perspective of the Brazilian private healthcare system. Methods: Using clinical and demographic inputs from the literature, we simulated a cohort of 5,000 severe allergic asthma patients and estimated the treatment cost with omalizumab. Results: In the simulated cohort, 81.3% were female, the mean body weight was 75.1 kg (SD 13.1), and the mean serum IgE was 532 IU/mL (SD 688). All patients were eligible for treatment with dupilumab, but 830 (16.6%) were ineligible for treatment with omalizumab due to serum IgE level and/or body weight combinations, according to the product label. Over four weeks, the mean dose of omalizumab was 537 mg (SD 285). The annual mean per-patient cost for treatment with omalizumab was BRL 110,783.89 (SD 58,385.81), ranging from BRL 31,797.49 to BRL 246,643.15. The treatment cost with dupilumab is BRL 111,724.21 for the first year and BRL 107,599.91 for subsequent years. Conclusions: We observed slightly lower mean treatment costs with dupilumab than with omalizumab. However, while the treatment cost with dupilumab is fixed and predictable, the treatment cost with omalizumab is highly variable, depending on patients’ characteristics. Health managers should consider these findings for reimbursement and clinical protocol development decisions. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Portuguese) Group: Ab Data: Objetivo: Comparar os custos de dupilumabe e omalizumabe para o tratamento de pacientes com asma alérgica grave na perspectiva do sistema de saúde privado brasileiro. Métodos: Utilizando parâmetros clínicos e demográficos a partir de dados da literatura, simulamos uma coorte com 5.000 pacientes com asma alérgica grave e estimamos o custo de tratamento com o omalizumabe. Resultados: Na coorte simulada, 81,3% eram do sexo feminino, com peso médio de 75,1 kg (DP 13,1) e IgE sérica de 532 IU/mL (DP 688). Todos os pacientes eram elegíveis para o tratamento com dupilumabe, porém 830 (16,6%) não eram elegíveis para o tratamento com omalizumabe devido a combinações específicas de IgE sérica e/ou peso corporal, de acordo com a bula do produto. Para o período de 4 semanas, a dose média de omalizumabe foi de 537 mg (DP 285). O custo médio anual por paciente do tratamento com omalizumabe foi de R$ 110.783,89 (DP 58.385,81), variando de R$ 31.797,49 a R$ 246.643,15. O custo do tratamento com dupilumabe é de R$ 111.724,21 no primeiro ano e R$ 107.599,91 nos anos seguintes. Conclusões: Foi observado que o custo médio do tratamento com dupilumabe é ligeiramente menor que o custo com omalizumabe. Todavia, enquanto o custo do tratamento com dupilumabe é fixo e previsível, o custo do tratamento com omalizumabe é altamente variável, dependendo de características dos pacientes. Esses achados devem ser considerados pelos gestores de saúde para decisões sobre reembolso e desenvolvimento de protocolos clínicos. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde is the property of JBES: Brazilian Journal of Health Economics and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=161425621 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.21115/JBES.v14.n3.p247-252 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 6 StartPage: 247 Subjects: – SubjectFull: DUPILUMAB Type: general – SubjectFull: ASTHMATICS Type: general – SubjectFull: OMALIZUMAB Type: general – SubjectFull: IMMUNOGLOBULIN E Type: general – SubjectFull: MEDICAL care Type: general – SubjectFull: ELECTROCONVULSIVE therapy Type: general Titles: – TitleFull: Cost comparison of dupilumab and omalizumab for the treatment of severe allergic asthma patients from the Brazilian private healthcare system perspective. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bighetti Magro, Frederico José – PersonEntity: Name: NameFull: Barbosa, Aline – PersonEntity: Name: NameFull: Taminato, Alexandre – PersonEntity: Name: NameFull: Borges Migliavaca, Celina – PersonEntity: Name: NameFull: Federico, Priscila – PersonEntity: Name: NameFull: Nahuys Tebyriçá, Renata – PersonEntity: Name: NameFull: Cançado, Jose Eduardo D. – PersonEntity: Name: NameFull: Giavina-Bianchi, Pedro – PersonEntity: Name: NameFull: Falavigna, Maicon IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: Dec2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 21752095 Numbering: – Type: volume Value: 14 – Type: issue Value: 3 Titles: – TitleFull: JBES: Brazilian Journal of Health Economics / Jornal Brasileiro de Economia da Saúde Type: main |
| ResultId | 1 |
